- Home
- PRLD vs PEPG Comparison
PRLD vs PEPG Comparison
Compare PRLD & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- PEPG
- Stock Information
- Founded
- PRLD 2016
- PEPG 2018
- Country
- PRLD United States
- PEPG United States
- Employees
- PRLD N/A
- PEPG N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- PEPG Health Care
- Exchange
- PRLD Nasdaq
- PEPG Nasdaq
- Market Cap
- PRLD 44.0M
- PEPG 45.9M
- IPO Year
- PRLD 2020
- PEPG 2022
- Fundamental
- Price
- PRLD $1.19
- PEPG $1.48
- Analyst Decision
- PRLD Strong Buy
- PEPG Buy
- Analyst Count
- PRLD 3
- PEPG 4
- Target Price
- PRLD $4.00
- PEPG $7.25
- AVG Volume (30 Days)
- PRLD 223.1K
- PEPG 340.0K
- Earning Date
- PRLD 11-05-2025
- PEPG 11-06-2025
- Dividend Yield
- PRLD N/A
- PEPG N/A
- EPS Growth
- PRLD N/A
- PEPG N/A
- EPS
- PRLD N/A
- PEPG N/A
- Revenue
- PRLD $7,000,000.00
- PEPG N/A
- Revenue This Year
- PRLD N/A
- PEPG N/A
- Revenue Next Year
- PRLD N/A
- PEPG N/A
- P/E Ratio
- PRLD N/A
- PEPG N/A
- Revenue Growth
- PRLD N/A
- PEPG N/A
- 52 Week Low
- PRLD $0.61
- PEPG $0.88
- 52 Week High
- PRLD $5.53
- PEPG $10.06
- Technical
- Relative Strength Index (RSI)
- PRLD 56.86
- PEPG 63.95
- Support Level
- PRLD $1.10
- PEPG $1.13
- Resistance Level
- PRLD $1.26
- PEPG $1.32
- Average True Range (ATR)
- PRLD 0.15
- PEPG 0.11
- MACD
- PRLD -0.00
- PEPG 0.03
- Stochastic Oscillator
- PRLD 70.65
- PEPG 48.66
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.